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RESUMO 
Objetivos: A Síndrome da Apneia Obstrutiva Do Sono (SAOS) é uma doença crónica, 
com consequências significativas a nível pessoal e social. A adesão ao tratamento por 
pressão positiva automática da via aérea (APAP) é muitas vezes inferior ao esperado, 
pondo em risco o sucesso do tratamento. Neste estudo, investigou-se a eficácia de uma 
intervenção educacional que utilizou estratégias motivacionais na adesão ao tratamento 
em doentes com SAOS. 
Desenho: Estudo randomizado e controlado. 
Local do estudo: Os pacientes foram recrutados sucessivamente da população de 
primeiras consultas de um laboratório de patologias de Sono. 
População: Sessenta e um pacientes diagnosticados com SAOS e com critérios para 
tratamento por APAP foram randomizados e alocados a um grupo de intervenção (GI) e 
dois grupos controlo (CG1 e CG2). 
Intervenção: No GI foram utilizadas estratégias motivacionais aplicadas de acordo com 
a fase de mudança do paciente, avaliada pela escala de confiança e convição. No CG1, 
os pacientes receberam exclusivamente informação padronizada e no GC2 foram 
seguidos os procedimentos de rotina. A adesão ao tratamento, foi avaliada ao primeiro 
(T1) e segundo (T2) mês de tratamento com APAP, recorrendo aos parâmetros 
registados no software do ventilador. 
Medidas e resultados: As variáveis em análise incluíram o índice de apneia/ hipopneia 
(IAH), Escala de Sonolência de Epworth (ESE), características socio demográficas e 
clínicas. O GI apresentou maior adesão ao APAP avaliada através da percentagem de 
dias de uso com mais de 4 horas de utilização (p=0.013), média de dias de uso efetivo 
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(p=0.000) e redução do índice de IAH (p=0.019) após dois meses de tratamento, quando 
comparado com os outros dois grupos. No GI o grau de confiança em usar o APAP 
aumentou de T1 para T2 (p=0.000). A ESE apresentou uma redução significativa 
(p=0.001) no GI e no CG2 (p=0.003) em T2 aumentando o seu score no CG2 (p=0.015). 
Conclusões: Na população estudada a intervenção implementada utilizando estratégias 
motivacionais aumentou a adesão ao APAP. 
Palavras chave: Síndrome da Apneia Obstrutiva do Sono, pressão positiva automática 
da via aérea, adesão, estratégias motivacionais. 
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ABSTRACT 
Study Objectives: Obstructive Sleep Apnea Syndrome (OSAS) is a serious disorder 
with significant personal and social consequences. Treatment adherence by Auto-
titrating Positive Airway Pressure (APAP) is often below expectations, challenging the 
expected outcomes. We investigated the effectiveness of a brief educational intervention 
using motivational strategies in treatment adherence among patients with OSAS. 
Design: Randomized controlled study  
Setting: Patients were consecutively recruited from first admissions in a Sleep 
Disorders Unit. 
Patients: Sixty one patients diagnosed with OSAS meting criteria for APAP therapy 
were randomly allocated to an intervention group (IG) and two control groups (CG1 and 
CG2). 
Interventions: In the IG motivational strategies were applied according to patient’s 
motivation, assessed by the degree of confidence and conviction. In the CG1, 
participants received exclusively standardized information and in the CG2 routine 
procedures were followed. Adherence to treatment was measured after one (T1) and two 
months (T2) through the APAP monitorization. 
Measurements and Results: Assessment included the Apnea Hypopnea Index (AHI), 
the Epworth Sleepiness Scale (ESS), socio demographic and clinical information. The 
IG presented higher adherence to APAP- percentage of days of use>4 hours (p=0.013), 
mean effective use per effective day (p=0.000) and lower AHI (p=0.019) at T2 when 
compared with the others two groups.  
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Confidence was higher in the IG group at T2 than at T1 (p=0.000). The ESS presented a 
significant reduction (p=0.001) in the IG and in the CG1 (p=0.003) at T2, but was 
higher in the CG2 (p=0.015). 
Conclusions: Brief interventions using motivational strategies can improve patient´s 
adherence to APAP.  
Key words: Obstructive Sleep Apnea Syndrome, Auto-titrating Positive Airway 
Pressure, adherence, motivational strategies. 
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INTRODUCTION 
1 Obstructive Sleep Apnea Syndrome 
Obstructive Sleep Apnea Syndrome (OSAS) has been considered in the past three 
decades a major health problem1. OSAS is a chronic sleep disorder characterized by 
partial reduction and/or total obstructions of breathing resulting from a predominantly 
inspiratory pharyngeal collapse during sleep2. This phenomenon occurs intermittently 
during sleep and leads to sleep fragmentation3. It is estimate that OSAS affects 
approximately 3-7% of male and 2-5% of females4. There are several risk factors 
responsible for the onset of OSAS, including male gender advanced age, obesity, 
craniofacial abnormalities, smoking and alcohol consumption5. On the other hand 
OSAS contributes to the onset of cardio respiratory and neuropsychiatric disorders6. 
Patients with severe OSAS have a higher prevalence of hypertension, arterial 
fibrillation, no sustained ventricular tachycardia7. The cognitive impairment, changes in 
personality and behavior are also frequent findings in patients affected by this disorder8. 
Other main consequence is an increased risk of traffic accidents due to a disturbed 
motor response9. Social relations are also affected and often these patients report social 
introversion, lack of interest in interpersonal relationships and marital problems10. 
According to the guidelines of the American Academy of Sleep Medicine11, OSAS 
severity can be defined by the Apnea Hypopnea Index (AHI) representing the number 
of apneas plus hypopneas per 1 hour of sleep. Scores equal to or greater than 5/h define 
the presence of OSAS, and can be subdivided into three severity levels: mild when the 
AHI is between 5 and 15/h, moderate when the AHI is between 15 and 30/h and severe 
when the AHI is above 30/h. 
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The main objective of the OSAS treatment is to reduce the resistance of the upper 
airway increasing the diameter of the oropharynx, consequently avoiding the 
appearance of obstructive apnea during sleep12. The gold standard method used is the 
application of continuous positive air pressure in the upper airway by a ventilator - 
Continuous Positive Apnea Pressure (CPAP) 13. With this device the air pressure is 
titrated in order to reduce AHI to 5 episodes per hour14, 15. The efficacy of the CPAP is 
well established: the daily use reduces AHI and drowsiness16, decreases blood pressure 
values17, improves the quality of life of the patients18 and of his partner19 and proved to 
be effective in reducing traffic accidents20. Marti and co-workers reported a reduced 
mortality rate in patients treated with CPAP21. 
Technical advances in positive-pressure therapy have led to the development and 
application of automatic systems for auto-titrating positive airway pressure (APAP) 13. 
2 Adherence therapy in patients with OSAS 
According to Taylor22 adherence can be defined as “the degree that the individual 
follows medical advice or recommendation associated with the disease”  
The criteria for adherence to PAP therapy, establish its use for more than 4 hours per 
night on 70% of the nights during a consecutive period of 30 days, in the first three 
months of treatment23. Some authors have reported that patients in long term treatment 
should use PAP for 4-5 hours on overage per night with a prescribed pressure24. 
Weaver and coworkers25 found that 6 hr per night are needed to normalize scores on the 
functional outcomes of sleepiness scale, whereas Campos-Rodriguez and coworkers26 
demonstrated significant benefit for cardiovascular events in individuals with 1 to 6 hr 
of nightly use compared to those using less than 1 hr per night. The author also found 
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that a regular adherence to treatment is necessary to improve the symptoms of OSAS 
and longitudinal studies have demonstrated a 5 years higher survival rate for patients 
who used the ventilator regularly, compared to nonusers.26. 
Adherence rates for the use of PAP showed to resist to the powerful arguments favoring 
this therapeutic approach. In a study carried out by Kribbs and coworkers27, the authors 
noted that in the first three months of treatment, less than 50% of patients used the 
ventilator positive airway pressure (PAP) for a minimum of 4 hours per night on 70% 
nights, and only 6% of the treated patients adhered to treatment at least 7 hours per 
night on 70% of the nights.  
Several factor are known to reduce patient`s adherence to PAP. Some are related to the 
technical characteristics of the equipment, and others result of the changes in life and 
stigma introduced by the ventilator treatment in patients routine28. A number of side 
effects may arise from the use of PAP; intolerance to the air pressure supplied by the 
ventilator, difficulty in exhaling air and air leaks to the outside of the mask24. Cutaneous 
intolerance to the mask, namely irritation, pain, rash and other skin lesions or irritation 
of the nasal mucosa are also frequent complains probably contributing to diminished 
adherence25.  
Educational programs also aimed to minimize these effects and enhance patients ‘ability 
to cope with the treatment20. Mounting attention has been given to the influence of the 
psychological factors on adherence to PAP, and Haniffa and collaborators29, concluded 
that “there is some evidence that psychological intervention/education improves 
adherence to PAP”. More recently a group education session proved to enhance the 
number of days of APAP use30. The progressive inclusion of monitoring programs in 
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ventilator devices permits a more objective assessment of the effective use of ventilation 
and to evaluate adherence to treatment31. 
3 Motivational Interview 
According to Miller and Rollinick, Motivational Interviewing (MI) is defined as a 
psychotherapeutic approach designed to trigger behavior change by helping the patient 
to explore and resolve ambivalence. For these authors, behavior change depends on 
motivation, the perception of the importance of the change and confidence in the ability 
to change32. A strong sense of purpose, clear strategies and skills for pursuing that 
purpose and a sense of timing to intervene in particular ways at incisive moments are 
core concepts of the MI33. Four fundamental principles guide MI practice: expressing 
empathy for the patient perspective, the development of discrepancy between values and 
behavior, rolling with resistance and support and amplify patient´s self confidence. For 
the change process to occur, the patients must engage in a thoughtful assessment and 
decision-making process about the change itself and self-evaluate their capacity to work 
through the change33: These two dimensions are defined as “conviction” and 
“confidence”. The easiest way to assess a patient’s conviction and confidence levels is 
to use a 0 to 10 ruler to help patients determine how important a change is and how 
confident he is in making that change34. 
Motivational Interviewing strategies have showed to be useful in enhancing adherence 
to preventive and therapeutic strategies 32, 35. Previous studies showed that MI can have 
a role in adherence to PAP, and is able to reduce the patient´s ambivalence about the use 
of the device36, 37. 
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The present study aimed to evaluate the effectiveness of an intervention using MI 
strategies in patient’s adherence to OSAS treatment using APAP. The intervention 
consisted in the implementation of strategies to increase motivation and reduce 
ambivalence linked to the use of ventilation procedures. The effective use of ventilation 
was collected through the device monitoring programs in all participants. 
 
MATERIAL AND METHODS 
Population 
 A total of 61 adults were invited to participate, recruited consecutively from a 
Sleep Disorders Unit. All participants had been previously diagnosed with OSAS, 
trough a cardiorespiratory polygraphic assessment. The assessment consisted of multi-
channels continuous polygraphic recording from nasal pressure transducer for nasal 
airflow, thoracic and abdominal impedance belts for respiratory effort, pulse oximetry 
and an intern microphone for snoring, in order to identify different types of apneas and 
hypopneas during sleep. Inclusion criteria were an AHI of 15/h or higher and indication 
for ventilator therapy. Regular procedures postulate that all selected participants are 
scheduled for a medical consultation and have access to the ventilator device in order to 
initiate therapy within for a maximum of seven days after the diagnosis. Participants 
with chronic obstructive pulmonary disease (COPD), neuromuscular disease, heart 
disease, neurological disease and patients taking psychotropic drugs were excluded 
from the study.  
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Procedures 
Forty one patients were allocated, according to a list of random codes generated 
by the Excel 2007 program, to the intervention group (IG) and the control group1 
(CG1). The control group 2 (CG2) was obtained from the remaining patients fulfilling 
the inclusion criteria. In IG and CG1 two questions were used to elicit patient’s 
conviction and confidence: “How important is for you the use of the ventilator in your 
treatment? and “How confident are you that you can use the ventilator?”. The degree of 
conviction and confidence permitted to establish the individual stage of change38 and to 
define specific strategies to be applied in an individual 10 minutes interview. During the 
intervention beliefs, expectations and feelings of the patient were assessed. We 
postulate according Prochaska and co-workers39-42 that a pré-contemplation stage 
corresponded to a score of 0 to 3, in each scale. At this stage, they were informed about 
the disease, the possible benefits of the treatment and of the risks of non compliance 
with the treatment. To be considered in the contemplation stage patients had to rate 
their conviction between 2 and 5 and their confidence between 5 and 8. At this stage, 
the intervention focused on emphasizing intrinsic motivation and reaffirming the 
autonomy of the patient choice. When patients rated their conviction between 6 and 8 
and their confidence between 7 and 10 they were considered in the preparation stage. 
In this stage, they were assisted to develop concrete plans and to clarify objectives. At 
the end of the session a new interview was scheduled and written information was 
delivered about OSAS disease and treatment. In the CG1, participants received 
exclusively standardized information about the ventilator and mask during a 10 minutes 
interview, regardless confidence and conviction scores and at the end of the session a 
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new interview was scheduled. The CG2 included patients submitted to routine 
procedures. 
One month latter the degree of conviction and confidence was reassessed in CG1 and IG 
patients. All participants were submitted to the standardized group educative session30, 
and the effective use of ventilation was assessed trough the APAP monitorization in all 
the participants. Participants flow, group allocation and procedures are detailed in 
Figure 1.  
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Figure 1 Participants selection Flowchart  IG - intervention group, CG1 - control 
group1; CG2 - control group2. 
 
Measures and instruments  
1. The AHI, provide a measure of OSAS severity and was determined in all the patients. 
A moderate to severe OSAS (AHI ≥15 events per hour) was used as inclusion criteria, 
according to the criteria of the American Academy of Sleep Medicine11. 
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2. Socio demographic information, tobacco and alcohol consumption were collected in 
all participants. Clinical information was obtained from the clinical file and included 
Body Mass Index (BMI) and medical comorbidities (hypertension, diabetes and 
dyslipidemia). 
3. The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire which 
provides a measure of a person’s general level of daytime sleepiness43, 44. There is a 
high level of internal consistency within the ESS, as assessed by Cronbach’s alpha 
statistic (alpha = 0.88).  
4. The APAP device used was AutoSet S9 (ResMed) and utilization was monitored 
using the Smart CardTM technology provided with the Resmes- Resscan, Software. 
Adherence was measure by the total number of hours of daily use at the prescribed 
pressure, the percentage of days of use, the mean effective use per effective day, and the 
residual AHI (events per hour). Adherence PAP definition, establish its use for more 
than 4 hours per night on 70% of the nights during a consecutive period of 30 days27.  
Statistical Analysis 
Data analyze was conducted using the Statistical Package Social Sciences (SPSS) 
version 20 .The significance level was set at 0,05 for all the analyzes. Data are reported 
as means, standard deviations, and percentages. Socio demographic and disease severity 
data were compared using Anova test and Tukey tests for group differences. The paired 
sample t-test was used to determine significant differences between the different groups 
of participants. The chi-square test was used to compare frequencies and proportions 
between groups. General linear Model repeated measures was used to compared 
differences between and within groups in different treatments moments. 
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Ethical considerations 
This study was submitted to and approved by the Ethical Committee of the Hospital São 
João EPE, approved data on 28 February 2013. Participants received information about 
the study after which they gave their written informed consent. The confidentiality and 
privacy of the collected data were guaranteed according to the Declaration of Helsinki. 
RESULTS 
1 Socio demographic and clinical characterization 
Sixty one patients were included in the present study with a median age of 56.5 (SD 
10.0) years. The majority were males (77%), predominantly married (93%) and with a 
low mean educational level of 7.1 (SD 3.5) years. Regarding professional status and 
alcohol consumption no differences were detected between the studied groups. On the 
contrary CG1 presented statistically significantly less regular smokers than the two 
other groups. Clinical variables namely BMI, Hypertension, Diabetes and Dyslipidemia 
were similar in all the participants, with a significant number of patients presenting high 
blood pressure (82%). The standardized OSAS evaluation revealed that the majority of 
the patients presented a severe form of the disorder regardless of the group (74%). Table 
1 presents the socio-demographic and clinical characterization of the three studied 
groups.  
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Table 1 Socio demographic and clinical characterization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a n (%); b mean (SD), c Tukey test; dChi-square test. BMI - Body Mass Index, AHI -Apnea Hypopnea Index, PY –Pack Years.  
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2 Adherence to APAP therapy  
Participant’s adherence to APAP treatment was evaluated after the first (T1) and second 
month (T2) in all participants. The percentage of days with more than four hours of 
APAP use, mean effective use of ventilation per day and AHI were used to assess 
adherence to ventilator therapy. Results showed that at T1 no statistically significant 
differences were detected between the groups. After two months of treatment (T2) on 
the contrary, a statistically significant higher use of APAP was detected in the IG, 
regarding the percentage of days used>4 hours (p=0.013) and the mean effective use per 
effective day (p=0.000) when compared with the others two groups. The AHI revealed a 
trend to a lower score in the IG participants (p=0.019) Comparing the T1 and T2 
measures in each group, statistically significant differences were detected in the IG 
regarding the percentage of days with more than four hours of ventilator use (p = 0.031) 
(Figure 2), and the mean effective use per effective day (p=0.011). In the CG1 the mean 
effective use per effective day presented a statistically significant lower value (p=0.003) 
(Table 2). 
Figure 2 - Percentage of days with more than 4 hours use in the three groups studied 
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Table 2 – Adherence to APAP therapy 
 
 
3 Conviction and confidence evaluation 
The conviction and confidence regarding the use of the APAP was assessed in IG and 
CG1 patients at T1 and T2. In the conviction score was similar in the two groups, and 
no differences were detected within each group when comparing the scores at the two 
evaluations. For the confidence scale a statistically significant higher sore was detected 
in the IG group at T2, when compared with T1 (p=0.000) and with CG1 at T2 (p=0.001) 
(Table 3 and Figure 3). 
 
a  mean (SD), b hour, *p<0.05,** p<0.005 
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Figure 3 - Confidence evaluation 
 
 
 
 
 
Table 3 – Conviction and confidence evaluation 
 
a= n (SD), * *p<0.005 
4  Evaluation of daytime sleepiness (ESS) 
The ESS scores at baseline were similar in the three groups (p=0.105). Comparing with 
baseline assessment, lower scores at the T1 and T2 evaluation were detected in all 
participants. In the IG group (p=0.000) and in the ICG1 (p=0.008).  
 IG 
n= 20 
CG1 
n=21 
 
p 
Conviction scale 
a 
T1 
T2 
 
8.6 (2.2) 
8.9 (1.6) 
 
8.9 (1.7) 
8.1 (2.7) 
 
0.563 
 
Confidence scale 
a 
T1 
T2 
 
7.2 (2.0) 
9.0 (1.6) ** 
 
8.7 (1.6) 
8.3 (2.9) 
 
0.066 
 
 
4
6
8
10
T1 T2
IG
CG1
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ESS score was statistically significantly lower in T1 when compared with T0, and when 
comparing T1 and T2 (p=0.001 and p=0.003 respectively). Interestingly in the CG2 the 
ESS score was higher in the T2 than in the T1 (p=0.015) (Figure 4).  
Figure 4 - Evaluation of daytime sleepiness (ESS) 
 
DISCUSSION 
Obstructive Sleep Apnea Syndrome is common disorder, with relevant health costs6-10 
associated with significant negative consequences for both the patient and family. 
Positive Airway Pressure (PAP) is the most commonly prescribed treatment for OSAS. 
Although efficient in reducing daytime sleepiness and mental and physical 
impairment45,46, PAP is a demanding treatment often reported by the patients as difficult 
to adhere. This study explores the application of a brief educational and motivational 
intervention aiming to improve APAP adherence in a group of naive user patients. 
In line with previously reported our sample presents a higher number of male patients 
with elevated Body Mass Index (BMI)47 and alcohol consumption48, physical and 
mental long term consequences of OSAS49, include an increased likelihood of 
developing chronic conditions namely hypertension, and other cardio vascular 
disorders50. Accordingly a significant proportion of the studied patients presented 
3
6
9
12
T0 T1 T2
IG
GC1
GC2
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hypertension, reinforcing the value of this PAP indication, recent evidence suggests that 
PAP may be effective in decreased blood pressure, and cardiovascular events17. 
This chronic disease has major implications in the sleep circle and recurrent sleep 
arousals and sleep fragmentation associated with the disorder may lead to daytime 
sleepiness51. In the present study daytime somnolence was evaluated with the ESS. 
Reinforcing the evidence that daytime sleepiness contributes to absence from work and 
decreased work productivity52 we detected a significant proportion of professionally 
inactive subjects in our sample. Moreover daytime sleepiness is a prevalent feature of 
the syndrome that may predict ongoing PAP use53. In our study the improvement of 
ESS scores was associated with higher APAP adherence. In agreement with Engleman 
and coworkers who found no correlation between severity of OSAS and PAP usage54 
we did not detect differences between the AHI severity and the adherence and no 
correlation between these two variables.  
Despite the numerous positive outcomes experienced by patients who use PAP, the 
effectiveness of this treatment is limited by suboptimal adherence rates55. “The simple 
yet important fact that treatment efficacy often depends on patient adherence”56 has 
raised the interest on motivational issues when patients need behavior change 
interventions and/or when the illness was chronic57. Motivational strategies have proved 
to be useful in helping patients to improve their adherence to therapeutic and preventive 
procedures36,37,58. Patient’s collaboration is crucial to adherence to PAP and compliance 
with side effects of the treatment59, and a significant number of studies have reported 
beneficial results emerging from educational and informative interventions30,36,37. The 
present study presents an original intervention using MI strategies applied in order to 
improve APAP adherence. A higher adherence was detected in the patients submitted to 
the educational and motivational intervention, according with the results reported in 
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adherence to medication and screening exams using similar approaches. Assessment 
was performed according recognized definitions of APAP adherence - percentage of 
days with more than four hours of APAP use, mean effective use of ventilation per 
day30, 60 and AIH.  
Moreover several of the earliest studies on APAP adherence were designed to examine 
short-term adherence rates15,25. We examined APAP use at 1 and 2 months of treatment, 
verifying an effective improvement at the second evaluation. Previous results have 
stated the importance of adherence maintenance and described different outcomes when 
interventions were assessed early on latter in treatment evolution61, 62. 
Confidence and conviction rulers were used to assess the patient’s stages of change and 
implement the adequate response from the technician. To determine the importance of 
APAP therapy (conviction) and patient’s belief in his ability to follow it (confidence) 
permitted to tailor information, discuss future plans and emphasize patient’s control. 
Similar results were found in the studied subjects at first evaluation, but an increased 
confidence was detected in the intervention group even before the adherence rates 
improvement. This increment, not seen in the group submitted to standardized 
information, point to the importance of assessing the readiness to change and even more 
to personalize the intervention, in order to enhance patient compliance. 
We confirmed that a brief interview (10 minutes length), using specify strategies 
according motivational phase, enhanced patients adherence to APAP therapy. To assess 
patients’ beliefs about their health, the disease and its risks, listening to their emotions 
and fears permitted to amplify their confidence. Tailored information about the possible 
benefits of the treatment, the risks of non compliance and helping to develop concrete 
plans and to clarify the importance of the daily use of ventilator therapy conducted to a 
more regular use of the treatment than delivery of exclusively standardized information.  
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This study has several limitations, namely the small number of participants and the 
absence of data on technical difficulties resulting from the interface of the APAP 
device. 
CONCLUSION 
In conclusion, when patients initiate PAP frequently report change in their life style14 
and several factors potentially influence the level of PAP compliance and overall 
adherence29, 31.The present study provides support for the benefit of motivational 
interventions in APAP adherence. Moreover results reinforce the feasibility and efficacy 
of a brief, tailored approach performed by prepared technicians. The socio demographic 
characteristics of our population also indicate that MI interventions are accessible and 
well accepted by populations with reduced educational achievement. Similar 
interventions could be applied and easily incorporated in routine care. 
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